Dear patient,
The new drug trabedersen (AP 12009) is currently being tested in different clinical studies. At present, the following trials are recruiting patients:
Brain tumors
An international clinical Phase III trial, known as the ‘SAPPHIRE’ study, is currently recruiting adult patients with recurrent or refractory anaplastic astrocytoma (high-grade glioma WHO grade III).
Tumors are defined as recurrent if they have been successfully treated, but have returned. Tumors are defined as refractory if they have been resistant to previous radio- or chemotherapy or other therapeutic treatment or are worsening. Trabedersen may not be used for the treatment of brain metastases from any other tumors. For further information, please visit our website www.anticancer.de.
Pancreatic carcinoma and malignant melanoma
A further clinical study of trabedersen (AP 12009), involving patients with pancreatic carcinoma or malignant melanoma is ongoing. Centers for this clinical Phase I/II study are located exclusively in Germany. For further information, please visit our website www.anticancer.de (German language only).
Due to international regulations, Antisense Pharma is not permitted to directly contact or care for patients. Only physicians involved in the clinical studies may do so. We kindly ask you to visit our website www.anticancer.de, respectively, for information about currently recruiting study centers and contact details. There you will find also background information on the drug trabedersen (AP 12009) and its use in cancer therapy.
We would like to point out that the drug trabedersen (AP 12009) is not yet approved for market. For legal reasons, its use is restricted to patients participating in our clinical studies and is not available from Antisense Pharma GmbH or any other source, therefore.
Further clinical studies are in preparation. We will inform you here about details in time.
Thank you!